AU2015237241B2 - L-2-hydroxyglutarate and stress induced metabolism - Google Patents

L-2-hydroxyglutarate and stress induced metabolism Download PDF

Info

Publication number
AU2015237241B2
AU2015237241B2 AU2015237241A AU2015237241A AU2015237241B2 AU 2015237241 B2 AU2015237241 B2 AU 2015237241B2 AU 2015237241 A AU2015237241 A AU 2015237241A AU 2015237241 A AU2015237241 A AU 2015237241A AU 2015237241 B2 AU2015237241 B2 AU 2015237241B2
Authority
AU
Australia
Prior art keywords
hypoxia
agent
level
tissue
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015237241A
Other languages
English (en)
Other versions
AU2015237241A1 (en
Inventor
Andrew M. INTLEKOFER
Craig B. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2015237241A1 publication Critical patent/AU2015237241A1/en
Application granted granted Critical
Publication of AU2015237241B2 publication Critical patent/AU2015237241B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7038—Hypoxia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
AU2015237241A 2014-03-28 2015-03-27 L-2-hydroxyglutarate and stress induced metabolism Ceased AU2015237241B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972091P 2014-03-28 2014-03-28
US61/972,091 2014-03-28
PCT/US2015/023038 WO2015148950A1 (en) 2014-03-28 2015-03-27 L-2-hydroxyglutarate and stress induced metabolism

Publications (2)

Publication Number Publication Date
AU2015237241A1 AU2015237241A1 (en) 2016-10-20
AU2015237241B2 true AU2015237241B2 (en) 2021-07-29

Family

ID=54196451

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015237241A Ceased AU2015237241B2 (en) 2014-03-28 2015-03-27 L-2-hydroxyglutarate and stress induced metabolism

Country Status (6)

Country Link
US (2) US10450596B2 (enExample)
EP (1) EP3122893B1 (enExample)
JP (2) JP6953305B2 (enExample)
AU (1) AU2015237241B2 (enExample)
CA (1) CA2943823C (enExample)
WO (1) WO2015148950A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780700B1 (en) 2011-11-18 2021-04-07 Memorial Sloan Kettering Cancer Center 2-hydroxyglutarate as a biomarker for chronic hypoxia
AU2015237241B2 (en) 2014-03-28 2021-07-29 Memorial Sloan-Kettering Cancer Center L-2-hydroxyglutarate and stress induced metabolism
WO2018148550A1 (en) * 2017-02-10 2018-08-16 Health Research, Inc. Targeting mitochondrial complex ii to reduce effects of chronic hypoxia
US10500318B1 (en) * 2018-07-03 2019-12-10 Temple Therapeutics BV Dosing regimens for treating hypoxia-associated tissue damage
JP6977999B2 (ja) * 2018-08-22 2021-12-08 国立大学法人京都大学 胚培養培地、及び胚培養方法
FR3097739B1 (fr) * 2019-06-25 2022-03-04 Lnc Therapeutics Bactéries du microbiote intestinal et composition en contenant pour son utilisation dans la prévention et/ou le traitement de maladies caractérisées par l’excès de 2-hydroxyglutarate
CN112830958B (zh) * 2021-02-05 2022-06-14 山东大学 一种特异性响应于d-2-羟基戊二酸的转录调控因子及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075065A1 (en) * 2011-11-18 2013-05-23 Memorial Sloan-Kettering Cancer Center 2-hydroxyglutarate as a biomarker for chronic hypoxia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20060084123A1 (en) 2001-12-13 2006-04-20 Harris Adrian L MN and hypoxia
WO2004046729A2 (en) 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
WO2009086215A2 (en) 2007-12-21 2009-07-09 Wyeth Pathway analysis of cell culture phenotypes and uses thereof
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
SE534542C2 (sv) 2009-09-30 2011-09-27 Calmark Sweden Ab Testsystem för bestämning av hypoxiutlöst cellskada
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US20120202883A1 (en) 2011-01-20 2012-08-09 Duke University Effects of idh1 and idh2 mutations on the cellular metabolome
AU2012347557A1 (en) * 2011-12-09 2014-07-03 Metabolon, Inc. Biomarkers for kidney cancer and methods using the same
US8977473B2 (en) 2012-08-29 2015-03-10 Caterpillar Inc. Pressure control strategy for dual fuel compression ignition engine and machine using same
AU2015237241B2 (en) 2014-03-28 2021-07-29 Memorial Sloan-Kettering Cancer Center L-2-hydroxyglutarate and stress induced metabolism

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075065A1 (en) * 2011-11-18 2013-05-23 Memorial Sloan-Kettering Cancer Center 2-hydroxyglutarate as a biomarker for chronic hypoxia

Also Published As

Publication number Publication date
WO2015148950A1 (en) 2015-10-01
JP2022008641A (ja) 2022-01-13
EP3122893B1 (en) 2021-06-02
EP3122893A4 (en) 2017-12-13
JP7208323B2 (ja) 2023-01-18
CA2943823A1 (en) 2015-10-01
US20170175164A1 (en) 2017-06-22
EP3122893A1 (en) 2017-02-01
US11788112B2 (en) 2023-10-17
AU2015237241A1 (en) 2016-10-20
CA2943823C (en) 2023-10-10
US10450596B2 (en) 2019-10-22
JP6953305B2 (ja) 2021-10-27
JP2017520774A (ja) 2017-07-27
US20200032315A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
US11788112B2 (en) L-2-hydroxyglutarate and stress induced metabolism
Lu et al. ACOT12-dependent alteration of acetyl-CoA drives hepatocellular carcinoma metastasis by epigenetic induction of epithelial-mesenchymal transition
Gangat et al. JAK2 unmutated erythrocytosis: 2023 update on diagnosis and management
Terunuma et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis
Ye et al. Serine catabolism regulates mitochondrial redox control during hypoxia
Wang et al. Ablation of LGR4 promotes energy expenditure by driving white-to-brown fat switch
Huang et al. SNAP25 inhibits glioma progression by regulating synapse plasticity via GLS-mediated glutaminolysis
He et al. A novel lncRNA MDHDH suppresses glioblastoma multiforme by acting as a scaffold for MDH2 and PSMA1 to regulate NAD+ metabolism and autophagy
Guo et al. Insulin gene enhancer protein 1 mediates glycolysis and tumorigenesis of gastric cancer through regulating glucose transporter 4
Ling et al. Serotonylation in tumor-associated fibroblasts contributes to the tumor-promoting roles of serotonin in colorectal cancer
Chen et al. CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression
Zhang et al. Aldehyde oxidase 1 promoted the occurrence and development of colorectal cancer by up-regulation of expression of CD133
Zhang et al. CBX7 suppression prevents ischemia-reperfusion injury-induced endoplasmic reticulum stress through the Nrf-2/HO-1 pathway
Salomone et al. SIRT5 rs12216101 T> G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease
Yuan et al. miR-338-3p inhibits cell growth, invasion, and EMT process in neuroblastoma through targeting MMP-2
Guo et al. Neddylation-dependent LSD1 destabilization inhibits the stemness and chemoresistance of gastric cancer
Liu et al. Novel role of L-2-HG in regulating HIF1A signaling pathway and iron death resistance in renal cancer brain metastasis
Liu et al. Crotonate suppresses breast cancer metastasis and promotes immunotherapy response by inducing ACSS2-mediated EZH2-K348 crotonylation
Tang et al. Serum proteomic and metabolomic profiling of hepatocellular carcinoma patients co-infected with Clonorchis sinensis
Chong et al. USP18 reduces the inflammatory response of LPS-induced SA-AKI by inhibiting the PI3K-AKT-NF-κB pathway and regulate apoptosis of cells
Ni et al. Membrane-associated ring–CH–type finger 2 protects against metabolic dysfunction-associated fatty liver disease by targeting fatty acid synthase
Chen et al. Transcription factor ZNF207 drives aerobic glycolysis and facilitates malignancy progression in hepatocellular carcinoma
Sun et al. KDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer via the lactate/hnRNPA1 lactylation/AR-V7 axis
Sanchez-Roman et al. Two Cockayne Syndrome patients with a novel splice site mutation–clinical and metabolic analyses
Stefanowicz-Rutkowska et al. Is there a relationship between the prevalence of autoimmune thyroid disease and diabetic kidney disease?

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired